Completed clinical trials

Our clinical trials program is bringing the world’s best treatments to patients with eye diseases.

Completed clinical trials

The following clinical trials have been conducted at the Queensland Eye Institute:


Protocol Number: CMOAPEYE0438
Phase: IV
Sponsor: Allergan
Information: Phase IV, open label, non randomised, prospective study of ozurdex in the treatment of diabetic macular oedema


Protocol Number: RTA255-P001
Phase: IV
Sponsor: Alcon Research
Information: Assessment of anatomical and functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion


Protocol Number: RFB002A2406
Phase: Observational
Sponsor: Novartis
Information: Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes


Protocol Number: CRFB002AAU17
Phase: IV
Sponsor: Novartis
Information: Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept


Protocol Number: GX29185
Phase: III
Sponsor: F. Hoffmann-La Roche
Information: A phase III, multicentre, randomised, double-masked, sham-controlled study to assess the safety and efficacy of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration


Protocol Number: IDEV-120-TTAN
Phase: Investigational
Sponsor: Johnson & Johnson Surgical Vision
Information: Clinical handleability and acceptability assessment of the TITAN modular cartridge delivery system


Protocol Number: NXGT-101-MER1
Phase: Investigational
Sponsor: Abbott Medical Optics
Information: Proof of concept study for next generation intraocular lens model MER001


Protocol Number: SH03050
Phase: Investigational
Sponsor: Amblyoptica (Holding)
Information: Trial of the amblyoptica device for binocular treatment of amblyopia


Protocol Number: IDEV-121-DELT
Phase: Investigational
Sponsor: Johnson & Johnson Surgical Vision
Information: Clinical handleability and acceptability assessment of the DELTA disposable delivery system


For the health and safety of our patients, staff and visitors, we ask you do not enter the QEI South Brisbane or QEI Clayfield facilities if you:

  • Have been in contact with a known case of COVID-19 
  • Have recently travelled overseas or interstate and have NOT undergone a two week quarantine 
  • Are awaiting COVID-19 test results
  • Have cold or fever symptoms (sore throat, coughing, sneezing etc)
  • Recently visited a COVID-19 hot spot (as identified on the Queensland Government website)

Please note that all visitors at this time will undergo contactless temperature checking. Our staff will also require the full names and contact details of all visitors to the building. 

Thank you for your cooperation at this time, please don't hesitate to contact us on 07 3239 5000 if you have any concerns.